FIGURE 1.

Anticancer therapy (top 5 therapies vs. other therapy) in first‐ and second line. A, Synovial sarcoma: anticancer therapy (top 5 vs other) in first line. In first line, the single agents included in "Other single agent systemic therapy" category are atezolizumab, cisplatin, gemcitabine, interferon gamma, ontuxizumab, other hormone antagonists and related agents, pazopanib, and trabectedin. B, Myxoid/round cell liposarcoma: anticancer therapy (top 5 vs other) in first line. In first line, the single agents included in "Other single agent systemic therapy" category are dacarbazine, gemcitabine, monoclonal antibodies, other vaccines, oxaliplatin, paclitaxel, pazopanib, ridaforolimus, temozolomide, and vaccines. C, Synovial sarcoma: anticancer therapy (top 5 vs other) in second line. In second line, the single agents included in "Other single agent systemic therapy" category are antilymphocyte immunoglobulin, atezolizumab, dacarbazine, doxorubicin, epirubicin, gemcitabine, immunostimulants, monoclonal antibodies, nivolumab, NY‐ESO‐1, other vaccines, pazopanib hydrochloride, sirolimus, sorafenib, temozolomide, and vaccines. D, Myxoid/round cell liposarcoma: anticancer therapy (top 5 vs other) in second line. In second line, the single agents included in "Other single agent systemic therapy" category are atezolizumab, dacarbazine, dasatinib, gemcitabine, ifosfamide, olaratumab, pembrolizumab, protein kinase inhibitors, selumetinib, sorafenib, sunitinib, and vaccines